Status:
COMPLETED
Long-term Safety and Tolerability of AFFITOPE AD01
Lead Sponsor:
Affiris AG
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Brief Summary
The purpose of this study is to assess the long-term tolerability and -safety of AFFITOPE AD01 applied during AFFiRiS 001
Eligibility Criteria
Inclusion
- Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver
- Patients having participated in AFFiRiS 001 and received at least 1 vaccination with AFFITOPE AD01
- Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits.
Exclusion
- Patients having received no vaccination with AFFITOPE AD01
- Contraindication for MRI imaging
- History of questionable compliance to visit schedule, patients not expected to complete the clinical trial
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00711139
Start Date
June 1 2008
End Date
November 1 2009
Last Update
May 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria, 1090